Mesoblastic nephroma: A report of the United Kingdom children's cancer and leukaemia group (CCLG)

• Published in: Pediatric blood & cancer Vol. 56; no. 5; pp. 744 - 748
• Main Authors: England, Richard J., Haider, Nadeem, Vujanic, Gordan M., Kelsey, Anna, Stiller, Charles A., Pritchard-Jones, Kathy, Powis, Mark
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.05.2011
• Subjects: Adjuvants; Age; Blood; Cancer; Chemotherapy; Chemotherapy, Adjuvant; Child, Preschool; Children; Clinical trials; Data processing; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Kidney; Kidney Neoplasms - pathology; Kidney Neoplasms - surgery; Leukemia; Male; Manganese; mesoblastic nephroma; neonate; Nephrectomy; Nephroma; Nephroma, Mesoblastic - pathology; Nephroma, Mesoblastic - surgery; Registries; renal neoplasm; Retrospective Studies; Risk factors; Survival Rate; Treatment Outcome; United Kingdom
• ISSN: 1545-5009; 1545-5017; 1545-5017
• DOI: 10.1002/pbc.22871

Background Mesoblastic nephroma (MN) is a rare tumour which occurs mainly in early infancy and for which primary nephrectomy is the treatment of choice. This study aimed to assess surgical complications and outcomes in this patient group and to re‐evaluate the age threshold of 6 months for recommending primary nephrectomy. Procedure A retrospective file review of all cases of MN registered in UK Children's Cancer and Leukaemia Group renal tumour trials between October 1991 and March 2008. Data from the trials were compared with data held by the National Registry of Childhood Tumours, Oxford. Results Forty‐seven (3.5%) confirmed cases of MN were found among 1346 registered renal tumours. Median age at diagnosis was 30 days (range birth‐3.8 years). MN was significantly more common in the first 3 months of life compared to between 3 and 6 months (33 vs. 2 cases). Seven cases occurred between 6 months and 1 year and only five cases occurred beyond 1 year of age. There was a significant difference in the age of diagnosis by histological subtype. There were 11 complications in the series; no registered patient developed a recurrent tumour; and all were alive at last follow‐up. Conclusions Outcome for children with MN is excellent at all ages, with little indication for adjuvant chemotherapy. Children presenting at <3 months of age, should be treated by primary nephrectomy. In those presenting aged >3 months, alternative diagnoses should be considered, especially in the presence of surgical risk factors. Pediatr Blood Cancer 2011;56:744–748. © 2011 Wiley‐Liss, Inc.